Vectura Group plc flutiform® k-haler®now available in Europe

TIDMVEC

Vectura Group plc

10 September 2018

flutiform(R) k-haler(R)now available in Europe

New breath-triggered ICS/LABA combination aerosol inhaler launches in UK

Chippenham, UK - 10 September 2018: The Mundipharma global network of independent associated companies has announced that flutiform(R) k-haler(R) is now available in Europe for adults and adolescents (aged 12 years and older) with asthma where the use of a combination product (inhaled corticosteroid, ICS, and long-acting <BETA>(2) -agonist, LABA) is appropriate. The new inhaler has initially been launched in the UK. Further launches are anticipated across European countries in the coming months.

Geraldine Venthoye, Executive Vice President, Pharmaceutical and Device Development, Vectura, commented: "Uncontrolled asthma is commonly associated with incorrect inhaler technique, coupled with poor adherence to therapy. The launch of this enhanced device, designed to help patients take their medicine and reduce critical errors, is a natural extension of the flutiform(R) franchise. Europe remains a competitive and challenging ICS-LABA market and the launch of the flutiform(R) k-haler(R) will help support continued growth."

The existing flutiform(R) pMDI (pressurised metered dose inhaler) combination treatment was developed by Vectura and launched in 2012 in Europe and ROW by Mundipharma and in 2013 in Japan by Kyorin. Vectura earns revenue from product supply and royalties from in-market net sales. In 2017 flutiform(R) generated total product supply and royalty revenue for Vectura of GBP68.5 million.

Ends

For more information, please contact:

 
Vectura Group plc 
David Ginivan - VP Corporate Communications          [phone] 
 Julia Wilson - Director Investor Relations           [phone] 
Consilium Strategic Communications                  [phone] 
Mary-Jane Elliott / Jessica Hodgson / David Daley 
 

About flutiform(R) k-haler(R)

flutiform(R) k-haler(R) is a novel asthma treatment for adults and adolescents (aged 12 years and older) where the use of a combination product (inhaled corticosteroid [ICS] and long-acting <BETA>2-agonist [LABA]) is appropriate. It is a unique breath-triggered inhaler utilising a patented 'kinked' valve - the k-valve(TM) . The device is activated with a low inspiratory force, and is designed to help patients who find it difficult to co-ordinate actuation and inhalation with a standard pMDI device.

About asthma

Asthma is a chronic inflammatory disorder of the airways which leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Patients with poorly managed asthma are at an increased risk of exacerbations, hospitalisation and death. Poorly managed asthma can also have a huge impact on a person's quality of life and day-to-day activities.

About Vectura

Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.

Vectura has eight key inhaled, two non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork.

Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products and through the development of high-quality generic alternatives to branded therapies.

For further information, please visit Vectura's website at www.vectura.com.

(R) FLUTIFORM is a registered trade mark of Jagotec AG and is used under licence

(R) K-HALER is a registered trade mark of Mundipharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAEANNNEEKPEFF

(END) Dow Jones Newswires

September 10, 2018 04:57 ET (08:57 GMT)